105822 results about "Organic chemistry" patented technology

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

Disclosed herein are modified split mirrored transposons or double-stranded split mirrored transposon (SMT) compositions and methods of using SMTs. The methods include producing SMTs and using SMTs for nucleic acid analysis.

A PARP1 inhibitor compound has a structure of: Formula (I), R1 and R4 are independently selected from H and an organic group. R2 and R3 are independently absent, H, or an organic group. Z1 and Z2 are independently C or N. L has the structure: Formula (II). Each X1 is independently selected from C and N. Each X2 is independently selected from C, N, O and S. n, m, p, q, r and s are each in the range 0 to 6. m+n, p+q, and r+s are each in the range 2 to 6. Each R5A, R5B, R5C, and R6 is independently absent, H, or an organic group. Qa, Qb, Qc are each independently a bond or an organic linker. The compounds are for use in medicine, e.g. for use in treating cancer. Also provided are compositions and kits comprising the compounds, and methods of synthesising the compounds.

Provided herein are compounds, such as compounds of Formula (I), Formula (l-A), Formula (l-B), or Formula (l-C), or pharmaceutically acceptable salts of any one thereof, useful for modulating KRAS GD12 and / or other G12 mutants.

The present disclosure relates to a fused heteroaryl compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to a fused heteroaryl compound represented by general formula (I'), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a therapeutic agent, especially a use thereof in the preparation of a medicament for inhibiting KRAS amplification and / or mutant activity. Each group in general formula (I') is as defined in the description.

Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.

Compounds of formula (I) useful as cancer treatment, the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of certain diseases or disorders are disclosed.

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro (propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro (propyl vinyl ether) unit of 4.3 to 6.0% by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 0.7 to 1.4 g / 10 min, and the number of functional groups of 20 or less per 106 main-chain carbon atoms.

Provided herein are compounds, such as compounds of Formula (I), Formula (l-A), Formula (l-AA), or Formula (l-BB), or pharmaceutically acceptable salts of any one thereof, useful for modulating KRAS GD12 and / or other G12 mutants.

An organic molecule is disclosed comprising:a first chemical moiety with a structure of formula I,andtwo second chemical moieties, each at each occurrence independently from another consisting of a structure of formula II,wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

Provided herein are compounds, such as compounds of Formula (I), Formula (l-A), Formula (l-AA), or Formula (l-BB), or pharmaceutically acceptable salts of any one thereof, useful for modulating KRAS GD12 and / or other G12 mutants. (I)

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro (propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro (propyl vinyl ether) unit of 5.6 to 6.38 by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 17.1 to 23.0 g / 10 min, and the number of functional groups of 50 or less per 106 main-chain carbon atoms.

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro(propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro(propyl vinyl ether) unit of 5.5 to 6.5% by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 36.1 to 49.9 g / 10 min, and the number of functional groups of 50 or less per 106 main-chain carbon atoms.

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro(propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro(propyl vinyl ether) unit of 4.4 to 5.28 by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 11.0 to 16.0 g / 10 min, and the number of functional groups of 50 or less per 106 main-chain carbon atoms.

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro(propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro(propyl vinyl ether) unit of 6.2 to 7.1% by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 28.0 to 35.9 g / 10 min, and the number of functional groups of 20 or less per 106 main-chain carbon atoms.

Provided herein are compounds having a Formula (I), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, and / or in treating various diseases such as cancer.

The invention relates to a disubstituted nitrogenous five-membered heteroaryl compound serving as a kinase inhibitor and application of the disubstituted nitrogenous five-membered heteroaryl compound. The chemical structure of the disubstituted nitrogenous five-membered heteroaryl compound disclosed by the invention is shown as a formula A, the compounds of the invention are CHK1 inhibitors. Therefore, the compounds of the present invention can be used for the treatment of cancer. # imgabs0 #

Disclosed herein are compounds having the Formula I: SHP-L-Hs (I) and pharmaceutically acceptable salts thereof, wherein SHP is a chemical entity that binds to SHP2 protein, L is a linker, and Hs is chemical entity that binds HSP90 protein. Pharmaceutical compositions comprising the disclosed compounds and their uses for treating diseases responsive to modulation of SHP2 protein are also provided.

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro(propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro(propyl vinyl ether) unit of 3.7 to 4.4% by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 28.0 to 34.0 g / 10 min, and the number of functional groups of 20 or less per 106 main-chain carbon atoms.

The invention provides a preparation method of a KRAS G12D intermediate. Specifically, the invention provides a method for preparing a compound as shown in a formula III. The preparation process is simple in route and high in overall yield, and the cost can be remarkably reduced. # imgabs0 #

The invention provides novel tetracyclic compounds and derivatives thereof, and pharmaceutical compositions thereof and methods for treating diseases and disorders, such as various types of cancer.

There is provided a copolymer containing tetrafluoroethylene unit and perfluoro(propyl vinyl ether) unit, wherein the copolymer has a content of perfluoro(propyl vinyl ether) unit of 2.4 to 3.48 by mass with respect to the whole of the monomer units, a melt flow rate at 372° C. of 0.8 to 1.4 g / 10 min, and the number of functional groups of 20 or less per 106 main-chain carbon atoms.

The invention relates to a compound shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate of the compound, and application of the compound in inhibiting or degrading Kras related diseases such as cancers. B-L-K (I)

The present disclosure provides a compound represented by structural Formula (I') : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with PI3K. This disclosure also features compositions containing the same as well as methods of using and making the same.